Wellington Management Group LLP Grows Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Wellington Management Group LLP grew its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 17.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 114,640 shares of the specialty pharmaceutical company's stock after acquiring an additional 16,784 shares during the quarter. Wellington Management Group LLP owned 0.36% of Collegium Pharmaceutical worth $4,430,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Foundry Partners LLC acquired a new position in shares of Collegium Pharmaceutical in the second quarter valued at approximately $492,000. Penserra Capital Management LLC acquired a new position in shares of Collegium Pharmaceutical in the third quarter valued at approximately $757,000. Squarepoint Ops LLC increased its stake in shares of Collegium Pharmaceutical by 194.5% in the second quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company's stock valued at $3,553,000 after buying an additional 72,874 shares during the period. BOKF NA acquired a new position in shares of Collegium Pharmaceutical in the second quarter valued at approximately $490,000. Finally, Renaissance Technologies LLC increased its stake in shares of Collegium Pharmaceutical by 8.0% in the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company's stock valued at $49,314,000 after buying an additional 113,300 shares during the period.

Collegium Pharmaceutical Trading Up 0.6 %

Shares of Collegium Pharmaceutical stock traded up $0.18 on Tuesday, reaching $30.90. 556,493 shares of the company's stock were exchanged, compared to its average volume of 446,935. The company has a market capitalization of $996.53 million, a P/E ratio of 13.14 and a beta of 0.80. Collegium Pharmaceutical, Inc. has a 52 week low of $28.97 and a 52 week high of $42.29. The firm's 50-day moving average is $33.06 and its two-hundred day moving average is $34.37. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Analyst Ratings Changes

Several analysts recently commented on COLL shares. HC Wainwright upped their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, September 5th. StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, October 23rd. Finally, Piper Sandler reiterated a "neutral" rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.